Diphtheria tetanus pertusis-hepatitis B vaccine - Bharat Biotech

Drug Profile

Diphtheria tetanus pertusis-hepatitis B vaccine - Bharat Biotech

Alternative Names: Comvac4; ComVac4-Hb; Diphtheria, tetanus, pertussis whole cell and recombinant hepatitis B vaccine - Bharat Biotech; DTwPHib - Bharat Biotech

Latest Information Update: 15 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bharat Biotech
  • Class Bacterial vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 15 Feb 2017 Bharat Biotech plans a phase III trial in infant volunteers in India (CTRI2017-01-007706)
  • 19 Feb 2016 Launched for Diphtheria in India (IM) before February 2016 (Bharat Biotech pipeline; February 2016)
  • 19 Feb 2016 Launched for Hepatitis B in India (IM) (Bharat Biotech pipeline; February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top